The Clinical Implications of Tumor Mutational Burden in Osteosarcoma

15Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.

Abstract

Background: Osteosarcoma (OTS) is aggressive bone malignancy without well-recognized prognosis biomarker. Tumor mutational burden (TMB) has been proved as effective biomarker in predicting clinical outcomes in several cancer types. However, its prognostic value in OTS remains unknown. In this study, we aim to evaluate the implication of TMB in OTS patients. Methods: To depict the landscape of somatic mutations in OTS, we performed Whole-Exome Sequencing (WES) on 31 OTS tissue samples and corresponding White Blood Cells (WBCs) as matched control. TMB was calculated as the total number of somatic alterations in coding regions normalized to the per sequenced genomic megabase (~30.4Mb in WES). The prognostic values of TMB were evaluated by Kaplan-Meier methods and Cox regression models. Results: The median age was 16.0 years at diagnosis, and 54.8% of patients were male. The most common genetic alterations were mainly involved in cell cycle and DNA damage response and repair, including H3F3A, TP53, MYC, and CDKN2A/B. The median progression-free survival (PFS) was 775.5 days in TMB-High (defined as third quartile of TMB value, <2.565) versus 351 days in TMB-Low (<2.565). All patients with TMB-High are PFS-Long (>400 days), while 36.4% of all patients with TMB-Low were PFS-Long (P=0.003). TMB were significantly greater in PFS-Long than in PFS-Short (<400 days) (P=0.002). Moreover, the median overall survival (OS) was 1,307 days in TMB-High versus 672.5 days in TMB-Low. Furthermore, TMB-High group had significantly improved PFS (P=0.04) and OS (P=0.03). Conclusions: TMB-High can be used as prognostic marker for OTS. Our findings demonstrate that TMB may be helpful in combination with traditionally clinicopathologic risk factors to optimize risk stratification and guide treatment decisions.

References Powered by Scopus

Trimmomatic: A flexible trimmer for Illumina sequence data

41994Citations
N/AReaders
Get full text

Fast and accurate long-read alignment with Burrows-Wheeler transform

8847Citations
N/AReaders
Get full text

A framework for variation discovery and genotyping using next-generation DNA sequencing data

8298Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Recent and Ongoing Research into Metastatic Osteosarcoma Treatments

71Citations
N/AReaders
Get full text

Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma

15Citations
N/AReaders
Get full text

Neoadjuvant systemic oncolytic vesicular stomatitis virus is safe and may enhance long-term survivorship in dogs with naturally occurring osteosarcoma

5Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Xie, L., Yang, Y., Guo, W., Che, D., Xu, J., Sun, X., … Tang, X. (2021). The Clinical Implications of Tumor Mutational Burden in Osteosarcoma. Frontiers in Oncology, 10. https://doi.org/10.3389/fonc.2020.595527

Readers' Seniority

Tooltip

Researcher 3

60%

PhD / Post grad / Masters / Doc 2

40%

Readers' Discipline

Tooltip

Medicine and Dentistry 3

50%

Design 1

17%

Biochemistry, Genetics and Molecular Bi... 1

17%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Save time finding and organizing research with Mendeley

Sign up for free